Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity.
Kai-Wen HoI-J U ChenYi-An ChengTzu-Yi LiaoEn-Shuo LiuHuei-Jen ChenYun-Chi LuYu-Cheng SuSteve R RofflerBo-Cheng HuangHui-Ju LiuMing-Yii HuangChiao-Yun ChenTian-Lu ChengPublished in: Journal of nanobiotechnology (2021)
Our results indicate that this "double-attack" strategy using CD20 Ab-mPEG scFv and PLD can retain the tumor targeting (first attack) and confer PLD tumor-selectivity (second attack) to enhance PLD internalization and improve therapeutic efficacy in liquid tumors.